网站主页 >> CAS数据库列表 >> 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid
2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid
|
|
- CAS号:
- 853929-59-6
- 英文名:
- 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid
- 英文别名:
- OGT 2115;(E)-2-(2-(4-(3-(4-Bromophenyl)acrylamido)-3-fluorophenyl)benzo[d]oxazol-5-yl)acetic acid;2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid;2-2-4-1-(4-Bromophenyl)-3-oxoprop-1-en-2-ylamino-3-fluorophenyl-1,3-benzoxazol-5-ylaceticacid;5-Benzoxazoleacetic acid, 2-[4-[[3-(4-bromophenyl)-1-oxo-2-propen-1-yl]amino]-3-fluorophenyl]-
- 中文名:
- 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid
- 中文别名:
- 化合物 T16380;OGT 2115,乙酰肝素酶抑制剂
- CBNumber:
- CB22518952
- 分子式:
- C24H16BrFN2O4
- 分子量:
- 495.3
- MOL File:
- 853929-59-6.mol
|
|
|
2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid化学性质
-
沸点:
-
685.9±55.0 °C(Predicted)
-
|
-
密度:
-
1.574±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at RT
-
|
-
溶解度:
-
Soluble to 10 mM in DMSO
-
|
-
形态:
-
Powder
-
|
-
酸度系数(pKa):
-
3.85±0.30(Predicted)
-
|
2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid性质、用途与生产工艺
OGT 2115 是一种有效的,细胞可渗透且口服活性的乙酰肝素酶 (heparanase) 抑制剂,IC50 为 0.4 μM。OGT 2115 具有抗血管生成特性 (IC50 为 1 μM)。OGT 2115 还抑制硫酸乙酰肝素的降解活性。
IC50: 0.4 μM (Heparanase)
Heparanase InhibitorOGT 2115 can suppress metastasis induced by endoplasmic reticulum (ER) stress in breast cancer cells, although not significantly. However, compared with the control group, the number and rate of migrated cells are significantly reduced following the exposure of the cells to Tunicamycin + OGT 2115. OGT 2115 significantly inhibits the invasion and migration induced by Adriamycin. Furthermore, the MTT assay results show that OGT 2115 does not decrease the anti-proliferative effect of Adriamycin.
When administered to mice, OGT 2115 (Compound 12d) shows a plasma concentration of ~10x the heparanase IC
50
following oral dosing at 20 mg/kg.
2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/04/30 | HY-100898 | 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid OGT 2115 | 853929-59-6 | 5mg | 800元 |
2024/04/30 | HY-100898 | 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid OGT 2115 | | 10 mM * 1 mLin DMSO | 880元 |
2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid
生产厂家
853929-59-6, 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid 相关搜索:
- 药靶配体
- C24H16BrFN2O4
- OGT 2115,乙酰肝素酶抑制剂
- 化合物 T16380
- 853929-59-6
- 2-2-4-1-(4-Bromophenyl)-3-oxoprop-1-en-2-ylamino-3-fluorophenyl-1,3-benzoxazol-5-ylaceticacid
- 5-Benzoxazoleacetic acid, 2-[4-[[3-(4-bromophenyl)-1-oxo-2-propen-1-yl]amino]-3-fluorophenyl]-
- (E)-2-(2-(4-(3-(4-Bromophenyl)acrylamido)-3-fluorophenyl)benzo[d]oxazol-5-yl)acetic acid
- OGT 2115
- 2-[4-[[3-(4-Bromophenyl)-1-oxo-2-propenyl]amino]-3-fluorophenyl]-5-benzoxazoleaceticacid